Mode
Text Size
Log in / Sign up
Phase 2 Completed N=54 Randomized Quadruple-blind Treatment

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

Source: ClinicalTrials.gov NCT01136655 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Aug 2013
Primary outcomePrimary: Average 12 Hour Forced Expiratory Volume in 1 Second (FEV1) — 1.546; 1.594; 1.603; 1.489 liters — p=<0.0001

Summary

This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.

Outcome Measures

OutcomeResultp-value
PRIMARY
Average 12 Hour Forced Expiratory Volume in 1 Second (FEV1)
1.546; 1.594; 1.603; 1.489; 1.603 <0.0001 sig
SECONDARY
FEV1 at 12 Hours After Study Medication Inhalation
1.641; 1.692; 1.731; 1.626; 1.709 <0.0001 sig
SECONDARY
Maximal FEV1 During the 12-hour Study Period
1.833; 1.889; 1.884; 1.777; 1.892 <0.0001 sig
SECONDARY
Urinary Excretion of Formoterol During the 12 Hours Following Inhalation of Study Drug
192.0; 366.3; 740.6; 658.7 <0.0001 sig

Eligibility Criteria

Inclusion Criteria

  • Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 1
  • Has a FEV1 measured at least 6 hours after the last dose of inhaled, short-acting β2-agonist (SABA) and at least 48 hours after the last dose of inhaled long-acting β2-agonist of =60% and =85% of predicted normal.
  • Demonstrated reversibility of FEV1 of =15% from pre short acting beta agonist level within 15 to 30 minutes after administration of a standard dose of short acting beta agonist

Exclusion Criteria

  • Has been hospitalized for >24 hours at least once or required emergency treatment or urgent care visit more than once for an asthma-related condition during the 6 months prior to Visit 1
  • Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 1.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01136655). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search